Ozempic (semaglutide) Disease area(s): Metabolic diseases Manufacturer(s): Novo Nordisk 2024 Sales (USD): $17.45 billion Why it sold so well: Novo Nordisks GLP-1 blockbuster for type 2 diabetes continued its impressive growth in 2024, with sales increasing by 26% year-over-year to DKK 120.3 billion ($17.45 billion)
[DOI] [PubMed] [Google Scholar] 61.Loomba R., Hartman M.L., Lawitz E.J., Vuppalanchi R., Boursier J., Bugianesi E., Yoneda M., Behling C., Cummings O.W., Tang Y., et al
Mutation combinations arising from a particular starting point were classified as shared if the same mutation combination occurred in at least one read of at least one replicate of the alternative starting point, and mutation combinations were classified as starting point specific if not
Ela a principal causa de insuficincia renal crnica nos pases desenvolvidos, estando tambm fortemente associada a outras doenas cardiovasculares e obesidade
This performance exceeded Wall Streets expectations by 20 percent
The drugs may become accessible to more people as the Trump administration pressures manufacturers to lower prices, while the drug makers are also engaged in efforts to grow their market share after the initial boom period for sales has waned
